课题基金 / 基金详情

项目摘要

项目成果

ROBIN R DETERDING的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. New therapies are being developed for the treatment of cystic fibrosis, based on insights into the pathophysiology of the disease. P2Y2 receptor agonists represent a novel approach to the treatment of CF that attempts to bypass defective CFTR in airway epithelia and, instead, take advantage of the integrated actions of this class of agents on mucociliary clearance that are not dependent on CFTR. These agents act by stimulating the P2Y2 receptor, which results in chloride ion (Cl-) and liquid secretion and the inhibition of sodium (Na+) absorption to hydrate the airway surface liquid layer and create a more normal periciliary fluid milieu, while also stimulating mucin secretion from goblet cells and increasing ciliary beat frequency. Denufosol tetrasodium (INS37217) inhalation solution (denufosol) is a novel second generation, chemically stable, selective P2Y2 receptor agonist under development by Inspire Pharmaceuticals, Inc. Denufosol may have the ability to restore or maintain mucociliary clearance in patients relatively early in the CF lung disease process, which may preserve lung function and lessen the inevitable repeat cycles of pulmonary bacterial colonization, pulmonary exacerbations, and chronic lung function decline. This multi-center, randomized, double-blind, placebo-controlled Phase 3 study will examine denufosol as an early intervention therapy to improve lung function relative to placebo in a relatively healthy CF patient population. Eligible patients will be randomized to receive either denufosol 60 mg or placebo three times daily for a 24-week treatment period. At the completion of the 24-week placebo-controlled portion of this study, all patients will receive 60 mg denufosol three times daily for an additional 24 weeks in a safety extension period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH CF LUNG DISEASE
  • 批准号:
    7374394
  • 项目类别:
  • 资助金额:
    $0.65万
  • 财政年份:
    2006
  • 负责人:
    ROBIN R DETERDING
  • 依托单位:
Pediatric Interstitial Lung Disease Conference
  • 批准号:
    6838425
  • 项目类别:
  • 资助金额:
    $3.0万
  • 财政年份:
    2004
  • 负责人:
    ROBIN R DETERDING
  • 依托单位:
Inhalation Solution in Subjects with Mild to Moderate CF
  • 批准号:
    7041039
  • 项目类别:
  • 资助金额:
    $1.79万
  • 财政年份:
    2004
  • 负责人:
    ROBIN R DETERDING
  • 依托单位:
海外基金